Demonstrates improved accuracy in urologic disease classification using risk-calibrated SERS analysis, indicating enhanced diagnostic potential.
Surface-enhanced Raman spectroscopy (SERS) combined with deep learning offers a noninvasive route for molecular screening of urologic diseases. Its broader analytical utility, however, is constrained by two coupled challenges: overconfident predictions near interclass boundaries and cross-device/acquisition-condition distribution shift. We therefore tested whether risk-calibrated patient-level SERS analysis could identify reportable outputs under the protocol-linked composite shift observed in the external data set. Internally, a derivative-guided dual-stream classifier with soft-risk retain/defer triage separated a trusted reportable subset from high-risk samples sent to manual review and kept accuracy above 95% among retained spectra. Externally, the workflow used guarded patient-level calibration-path selection followed by support-dependent few-shot covariance alignment to recover covered known-class outputs under a cross-device/acquisition-condition composite shift. Across the four covered external classes, patient accuracy recovered to 85.82%, and accuracy among retained patients reached 89.95%. When prostate cancer was added to the external test stream as unknown input, a front-end dual-evidence gate increased the unknown patient defer rate from 4.80% to 78.40% while maintaining 90.07% accuracy among gate-passed known-class patients. The evaluation therefore goes beyond closed-set accuracy, testing internal release/defer control, few-shot calibrated recovery of covered external classes, and prereport deferral of unsupported inputs.
No takes yet. Share an insight, caveat, or question.
She et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: